Loading...
•
Mar 31, 2024
Ultragenyx Q1 2024 Earnings Report
Ultragenyx reported Q1 2024 financial results with total revenue of $109 million and reaffirmed its 2024 financial guidance.
Key Takeaways
Ultragenyx reported $109 million in total revenue for the first quarter of 2024, representing 8% growth compared to the same period in 2023. Crysvita revenue was $83 million, a 9% increase year-over-year, while Dojolvi revenue was $16 million, a 14% increase year-over-year. The company reaffirmed its full-year 2024 revenue guidance.
Total revenue for Q1 2024 was $109 million, an 8% increase compared to Q1 2023.
Crysvita revenue for Q1 2024 was $83 million, a 9% increase compared to Q1 2023.
Dojolvi revenue for Q1 2024 was $16 million, a 14% increase compared to Q1 2023.
The company reaffirms 2024 total revenue guidance between $500 million to $530 million.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Ultragenyx Revenue by Geographic Location
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comEvkeeza Revenue
CapyFin.comMepsevii Revenue
CapyFin.comRevenue by Geographic Location
Latin America and Türkiye Revenue
CapyFin.comU.S. and Canada Revenue
CapyFin.comEurope Revenue
CapyFin.com Forward Guidance
Ultragenyx reaffirms its full-year 2024 financial guidance, with total revenue expected to be in the range of $500 million to $530 million, Crysvita revenue in the range of $375 million to $400 million, and Dojolvi revenue in the range of $75 million to $80 million. Net Cash Used in Operations to be less than $400 million
Positive Outlook
- Total revenue in the range of $500 million to $530 million
- Crysvita revenue in the range of $375 million to $400 million. This includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.
- Dojolvi revenue in the range of $75 million to $80 million
- Net Cash Used in Operations to be less than $400 million
- Expect additional Phase 2 data update in second half of 2024
Revenue & Expenses
Visualization of income flow from segment revenue to net income